Eargo is a medical devices business based in the US. Eargo shares (EAR) are listed on the NASDAQ and all prices are listed in US Dollars. Eargo employs 243 staff and has a trailing 12-month revenue of around $41.1 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $2.62 |
| 200-day moving average | $3.13 |
| Wall St. target price | $2.00 |
| PE ratio | 0.1713 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $15.00 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Eargo stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eargo's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Eargo's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Eargo shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Eargo's P/E ratio is best considered in relation to those of others within the medical devices industry or those of similar companies.
| Revenue TTM | $41.1 million |
|---|---|
| Gross profit TTM | $14.3 million |
| Return on assets TTM | -60.08% |
| Return on equity TTM | -2457.08% |
| Profit margin | -263.14% |
| Book value | $2.17 |
| Market Capitalization | $53.4 million |
TTM: trailing 12 months
We're not expecting Eargo to pay a dividend over the next 12 months.
You may also wish to consider:
Eargo's shares were split on a 1:20 basis on 17 January 2023 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Eargo shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Eargo shares which in turn could have impacted Eargo's share price.
Over the last 12 months, Eargo's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eargo's is 1.478. This would suggest that Eargo's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Eargo's beta into context you can compare it against those of similar companies.
Eargo, Inc. , a medical device company, engages in enhancing the quality of life of people with hearing loss in the United States. It markets and sells hearing aids. The company sells its products direct-to-consumer and through omni-channel. The company was formerly known as Aria Innovations, Inc. and changed its name to Eargo, Inc. in November 2014.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
These are the stocks to buy when you don’t have much to spend.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Thinking of switching from Moomoo? Here are 5 apps like Moomoo that offer valuable benefits
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.